1032313-88-4

Basic information

• Product Name: C₅₅H₅₈N₂O₁₆S₂
• Synonyms: C₅₅H₅₈N₂O₁₆S₂
• CAS NO: 1032313-88-4
• Molecular Weight: 1067.2
• Mol File: 1032313-88-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: C₅₅H₅₈N₂O₁₆S₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₅₅H₅₈N₂O₁₆S₂(1032313-88-4)
• EPA Substance Registry System: C₅₅H₅₈N₂O₁₆S₂(1032313-88-4)

Safety Data

• Hazardous Substances Data: 1032313-88-4(Hazardous Substances Data)

Upstream product

• 111625-28-6 2-(2-(Pyridin-2-yl)disulfanyl)ethanol 
• 2127-03-9 2,2'-dipyridyldisulphide 
• 742091-98-1 2-(pyridin-2-yldisulfanyl)ethyl (6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazol-1-yl) carbonate 
• 33069-62-4 taxol 
• 874302-76-8 4-nitrophenyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate 

Downstream Products

• 1041170-95-9 C₅₄H₆₂N₂O₁₈S₂ 

Relevant articles and documents

Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation

To increase the selectivity of chemotherapeutic agents, receptor-mediated tumor-targeting approaches have been developed. Here, degarelix [Ac-D-Nal-D-Cpa-D-Pal-Ser-Aph(L-Hor)-D-Aph(Cbm)-Leu-ILys-Pro-D-Ala-NH2], a gonadotropin-releasing hormone antagonist, was employed as a targeting moiety for paclitaxel (PTX). Five PTX-degarelix conjugates were synthesized, in which PTX was attached via disulfide bond to the different position in the degarelix sequence. All of the PTX-degarelix conjugates exhibited a half-life greater than 10h determined in human serum. A fluorometric imaging plate reader assay showed that the conjugates LK-MY-9 and LK-MY-10 had an antagonism efficacy similar to that of degarelix. The in vitro cytostatic effects of the conjugates were determined by a (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, and the 50% inhibitory concentration value of the conjugates on 3T3 mouse embryonic fibroblast cells were one order of magnitude higher than the 50% inhibitory concentration values of the conjugates on MCF-7 human breast cancer cells and HT-29 human colon cancer cells. Receptor saturation tests further demonstrated that pre-incubation of the cells with degarelix reduced the efficacy of LK-MY-10 in a concentration-dependent manner. In conclusion, degarelix is a valid and stable moiety that has great potential for targeting chemotherapy drugs.

Water-soluble anti-tumor compounds

The invention relates to a water-soluble antitumor compound represented by the formula (I), and further relates to a preparation method of the compound and an application of the compound in preparation of antitumor drugs. Stable prodrug with a good water

COMPOSITIONS AND METHODS FOR TRANSPORT OF MOLECULES WITH ENHANCED RELEASE PROPERTIES ACROSS BIOLOGICAL BARRIERS

Conjugates of a cargo molecule with a transporter molecule are disclosed, where the cargo molecule and the transporter molecule are linked covalently by a releasable linker. The cargo of the conjugate can be a biologically active agent or a reporter molec